StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Thursday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Price Performance

TherapeuticsMD stock opened at $1.84 on Thursday. The firm has a 50-day moving average price of $1.94 and a two-hundred day moving average price of $2.12. TherapeuticsMD has a 52-week low of $1.43 and a 52-week high of $4.35.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.07) earnings per share for the quarter. The firm had revenue of $0.31 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the first quarter, according to its most recent filing with the SEC. The firm bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned about 0.21% of TherapeuticsMD at the end of the most recent quarter. Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.